{
    "clinical_study": {
        "@rank": "55304", 
        "arm_group": [
            {
                "arm_group_label": "Plexiform Neurofibroma", 
                "description": "NF1 associated plexiform neurofibroma"
            }, 
            {
                "arm_group_label": "Optic Glioma", 
                "description": "NF1 associated optic glioma"
            }
        ], 
        "brief_summary": {
            "textblock": "This prospective pilot study is designed to provide preliminary data on the use of\n      Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in\n      patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma\n      (PN).\n\n      Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12\n      months, unless more frequent imaging is clinically indicated.  Subjects and their family\n      caregivers will also undergo serial interviews and complete questionnaires related to the\n      psychosocial aspects of NF1."
        }, 
        "brief_title": "PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neurofibromatosis-1", 
            "Optic Glioma", 
            "Plexiform Neurofibroma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Neurofibroma", 
                "Neurofibromatoses", 
                "Neurofibromatosis 1", 
                "Osteitis Fibrosa Cystica", 
                "Neurofibroma, Plexiform", 
                "Optic Nerve Glioma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or\n             plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of\n             progressive disease\n\n          -  \u2265 6 years of age\n\n          -  English-speaking\n\n          -  If female of child-bearing potential, negative urine pregnancy test performed within\n             7 days prior to each FDG-PET-MRI\n\n          -  Study-specific informed consent or assent obtained and signed\n\n        Exclusion Criteria:\n\n          -  Unable to undergo FDG-PET-MRI without sedation\n\n          -  Currently undergoing chemotherapy for progressing optic glioma\n\n          -  Pregnant or lactating female\n\n          -  Poorly controlled diabetes mellitus\n\n          -  Presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo\n             device, epicardial pacemaker leads, or any other device that makes MRI unsafe\n\n          -  Serum creatinine > 1.8 mg/dL OR GFR < 30 mL/min\n\n          -  Unable to lie flat for > 1 hour\n\n          -  Body Mass Index (BMI) > 35"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "UNC Hospitals"
            }
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800032", 
            "org_study_id": "LCCC1222"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 25, 2013", 
        "location": {
            "contact": {
                "email": "riguera@email.unc.edu", 
                "last_name": "Dorothy Riguera, BS", 
                "phone": "919-843-5420"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599"
                }, 
                "name": "University of North Carolina-Chapel Hill"
            }, 
            "investigator": [
                {
                    "last_name": "Timothy Gershon, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Julie Blatt, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Stuart Gold, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Greenwood, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "J. Keith Smith, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amir Khandani, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sheila Santacroce, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hong Yuan, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)", 
        "overall_contact": {
            "email": "riguera@email.unc.edu", 
            "last_name": "Dorothy Riguera, BS", 
            "phone": "919-843-5420"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Timothy Gershon, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Ratios of SUVmax values within a group of patients who all have progressive disease", 
                "measure": "Plexiform Neurofibroma Cohort: Difference in FDG-avidity between progressive and non-progressive lesions", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Optic Glioma Patients: Compare FDG-avidity between patients with progressive and non-progressive disease", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SUV max, tumor/brain uptake ratio, tumor/muscle uptake ratio", 
                "measure": "Report descriptive statistics for FDG-PET-MRI results", 
                "safety_issue": "No", 
                "time_frame": "0, 12 months"
            }, 
            {
                "measure": "Explore impact of FDG-PET-MRI surveillance on patient and family caregiver uncertainty and psychological distress", 
                "safety_issue": "No", 
                "time_frame": "0, 12 months"
            }
        ], 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}